Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients

2019 ◽  
Author(s):  
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Dry Eye ◽  
Eye Drops

scholarly journals Relationship between electronically measured medication adherence and vision-related quality of life in a cohort of patients with open-angle glaucoma

2018 ◽  
Vol 3 (1) ◽  
pp. e000114 ◽  
Author(s):  
Atalie C Thompson ◽  
Sandra Woolson ◽  
Maren K Olsen ◽  
Susanne Danus ◽  
Hayden B Bosworth ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Medication Adherence ◽  
Open Angle Glaucoma ◽  
Mean Difference ◽  
Eye Drops ◽  
Open Angle ◽  
Related Quality ◽  
Adjusted Model

ObjectiveTo investigate whether electronically measured medication adherence is associated with vision-related quality of life (VRQoL) in patients with open-angle glaucoma.Methods and analysisThis is a 3-year prospective cohort study of 79 subjects with open-angle glaucoma at a Veterans Affairs medical centre. Participants returned a medication event monitoring system (MEMS) for their glaucoma eye-drops and had at least two visits with glaucoma during the study period. Those taking less than 80% of prescribed glaucoma medication doses were considered to be non-adherent. Subjects were interviewed using the National Eye Institute’s Visual Function Questionnaire-25 (VFQ-25) at baseline and after 3 years.ResultsThirty per cent (n=24/79) of participants took less than 80% of prescribed doses of their glaucoma medications at baseline. Patients who did not adhere to their medications at baseline had lower mean composite VFQ-25 scores at baseline (70.66±20.50 vs 75.91±19.12, standardised mean difference=0.27) and after 3 years (71.68±21.93 vs 76.25±21.67, standardised mean difference=0.21). Visual acuity (P=0.03), but not visual field severity (P=0.13) or medication adherence (P=0.30), was significantly associated with composite VFQ-25 score in an adjusted model.ConclusionsSubjects who were non-adherent to their glaucoma medications at baseline as assessed by a MEMS device reported lower VRQoL than adherent subjects at baseline and after 3 years. However, visual acuity was significantly associated with VRQoL. Future studies should assess whether improved adherence to eye-drops impacts VRQoL in patients with glaucoma.

scholarly journals Application of diphenydramine ointment to the eyelids for allergic conjunctivitis

2021 ◽  
Vol 3 (1) ◽  
pp. 44-50
Author(s):  
Mitsuhiro Kamimura ◽  
◽  
Takako Ohnishi ◽  
Hisao Terada ◽  
Atsuto Mouri ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Intraocular Pressure ◽  
Visual Analogue Scale ◽  
Analogue Scale ◽  
Allergic Conjunctivitis ◽  
Adverse Reactions ◽  
Eye Drops ◽  
Local Skin

Introduction: Allergic conjunctivitis is treated with oral anti-allergy agents or topical eye drops, but the response is often incomplete, and symptoms persist. We considered that topical treatment with an antihistamine ointment (diphenhydramine-Restamin Cream®) on the eyelids could be effective as supplemental therapy. This study investigates the efficacy and safety of Restamin Cream® for allergic conjunctivitis. Methods: In patients with allergic conjunctivitis, Restamin Cream® was applied to both eyelids twice a day for 2 weeks. There was a 2-week observation period before treatment and a 2-week washout period after treatment. Patients recorded symptoms (eye itching and watering) on a visual analogue scale for the entire 6-week period. Assessment of quality of life, evaluation of conjunctivitis, and measurement of visual acuity and intraocular pressure were conducted at the start of observation, at initiation of treatment, at completion of treatment, and at the end of washout. Results: 7 patients were enrolled; 5 completed the study and 2 discontinued due to adverse reactions. The quality of life score and objective ocular findings improved in all 5 patients. Visual analogue scale scores for itching and watering also improved significantly in 3 and 2 patients, respectively. Adverse reactions included local skin irritation in 3/7 patients, and transient blurred vision and eye pain in 1 patient each. There were no changes of visual acuity or intraocular pressure. Conclusions: Application of diphenhydramine ointment to the eyelids was effective for allergic conjunctivitis.

Psychosocial indicators of primary congenital glaucoma and filtering surgeries impacts on children and family’s quality of life

2021 ◽  
pp. 112067212110483
Author(s):  
Andrea Oliveira da Silva ◽  
Christiane Rolim-de-Moura ◽  
Nara Lúcia Poli Botelho ◽  
Carolina PB Gracitelli ◽  
Nívea Nunes Ferraz
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Intraocular Pressure ◽  
Surgical Treatment ◽  
Optic Disk ◽  
Congenital Glaucoma ◽  
Eye Drops ◽  
Primary Congenital Glaucoma ◽  
Corneal Diameter

Purpose: To identify psychosocial indicators and evaluate the filtering surgeries impacts on quality of life (QOL) of children with primary congenital glaucoma (PCG) and their family. Methods: Parents of children with bilateral PCG who underwent filtering surgery were included. Data were collected through: (a) psychological inquiry to determine psychosocial indicators; (b) Children’s Visual Function Questionnaire (CVFQ). The associations between the CVFQ scores and visual acuity, intraocular pressure, optic disk cupping, horizontal corneal diameter, axial length, number of surgeries, and hypotensive eye drops were investigated. The statistical significance level was considered as p ⩽ 0.05. Results: The mean age of the nine mothers interviewed and their children (six boys and three girls) was 29 ± 5 years and 35 ± 18 months, respectively. The psychosocial indicators determined were: emotional impact of the diagnosis, disease knowledge, mother and family’s feelings on facing the surgical treatment, surgical result comprehension, treatment adherence, child's emotional and behavioral reactions, social support, and future expectations. In CVFQ analysis, QOL score was strongly associated with visual acuity ( r = −0.79; p = 0.01). Besides the treatment score was correlated to intraocular pressure ( r = −0.68; p < 0.05), optic disk cupping ( r = −0.85; p = 0.03), and corneal diameter ( r = −0.69; p = 0.02). Correlations were not found for number of surgeries and eye drops. Conclusions: This study confirmed the PCG surgical treatment impact on QOL and determined psychosocial indicators which may favor the suitable actions in psychological treatment and follow-up of the children and families.

Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness

2018 ◽  
Vol 28 (4) ◽  
pp. 385-392 ◽  
Author(s):  
Anton Hommer ◽  
Doreen Schmidl ◽  
Martina Kromus ◽  
Ahmed M Bata ◽  
Klemens Fondi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Film Thickness ◽  
Dry Eye ◽  
Ocular Surface ◽  
Tear Film ◽  
Eye Drops ◽  
Life Score ◽  
Related Quality ◽  
Preservative Free

Purpose: Long-term glaucoma therapy with preservative-containing eye drops may impact ocular surface health. This study was performed to investigate whether a switch from preserved topical prostaglandin therapy to preservative-free tafluprost therapy improves precorneal tear film thickness in patients with glaucoma or ocular hypertension. Methods: A total of 30 patients who were under topical preservative-containing prostaglandin monotherapy for at least 6 months were included. Patients were then switched from preserved prostaglandin therapy to unpreserved tafluprost drops once daily. Tear film thickness was measured at baseline and 4 and 12 weeks after therapy change with an ultrahigh-resolution optical coherence tomography system. Furthermore, clinical measures of ocular surface disease were determined and symptoms were assessed using the Dry Eye–Related Quality-of-Life Score. Results: After switching to unpreserved tafluprost, tear film thickness significantly increased from 4.7 ± 0.5 to 5.0 ± 0.6 µm 4 weeks after therapy change and still tended to be increased after 12 weeks (4.8 ± 0.7 µm). Breakup time significantly increased from 5.1 ± 2.3 to 7.2 ± 3.4 s and to 10.1 ± 3.6 s after therapy change. In addition, a significant decrease in corneal staining score from 1.8 ± 0.7 to 1.4 ± 0.8 after 4 weeks and to 0.7 ± 0.7 after 12 weeks treatment was observed. Switching to preservative-free drops reduced Dry Eye–Related Quality-of-Life Score from 11.4 ± 11.0 to 5.7 ± 6.4 and to 4.7 ± 7.5. Conclusion: Our data show that switching to preservative-free tafluprost leads to an increase in tear film thickness, breakup time, and an improvement of Dry Eye–Related Quality-of-Life Score. Our results therefore indicate that a switch to unpreserved tafluprost is beneficial for ocular surface health in patients under long-term preserved prostaglandin eye drops.

scholarly journals Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting

2017 ◽  
Vol 15 (2) ◽  
pp. 169-178 ◽  
Author(s):  
José Benítez-del-Castillo ◽  
Marc Labetoulle ◽  
Christophe Baudouin ◽  
Maurizio Rolando ◽  
Yonca A. Akova ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Dry Eye ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Group Meeting

scholarly journals Topical TRPM8 Agonist for Relieving Neuropathic Ocular Pain in Patients with Dry Eye: A Pilot Study

2021 ◽  
Vol 10 (2) ◽  
pp. 250
Author(s):  
Hyeon Jeong Yoon ◽  
Jonghwa Kim ◽  
Jee Myung Yang ◽  
Edward T. Wei ◽  
Seong Jin Kim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
Pain Intensity ◽  
Dry Eye ◽  
Associated Factors ◽  
Treatment Result ◽  
Ocular Pain ◽  
Eye Pain ◽  
Validated Questionnaire

Background: Activation of TRPM8, a cold-sensing receptor located on the cornea and eyelid, has the potential to relieve the neuropathic ocular pain (NOP) in dry eye (DE) by inhibiting other aberrant nociceptive inputs. We aimed to investigate the effect of a topical TRPM8 agonist, cryosim-3 (C3), on relieving DE-associated NOP. Methods: We conducted a prospective pilot study of 15 patients with DE-associated NOP. These patients applied topical C3 to their eyelid, 4 times/day for 1 month. The patients underwent clinical examinations. They also completed the Ocular Pain Assessment Survey (OPAS), which is a validated questionnaire for NOP, at baseline, 1 week, and 1 month after treatment. Result: At 1 week, the OPAS scores of eye pain intensity, quality of life (driving/watching TV, general activity, sleep, and enjoying life/relations with other people), and associated factors (burning sensation, light sensitivity, and tearing) improved. The total OPAS scores of eye pain intensity, quality of life, and associated factors remained improved at 1 month. The Schirmer test scores also improved at 1 month. Conclusion: TRPM8 agonist (C3) could be a novel agent for treating patients with DE-associated NOP who are unresponsive to conventional treatments.

Visual acuity and quality of life outcomes in patients with cataract in Shunyi County, China

1998 ◽  
Vol 126 (4) ◽  
pp. 515-523 ◽  
Author(s):  
Jialiang Zhao ◽  
Ruifang Sui ◽  
Lijan Jia ◽  
Astrid E Fletcher ◽  
Leon B Ellwein
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Life Outcomes ◽  
Quality Of Life Outcomes

Dry Eye Syndrome-Related Quality of Life in Glaucoma Patients

2009 ◽  
Vol 19 (4) ◽  
pp. 572-579 ◽  
Author(s):  
Gemma Caterina Maria Rossi ◽  
Carmine Tinelli ◽  
Gian Maria Pasinetti ◽  
Giovanni Milano ◽  
Paolo Emilio Bianchi
Keyword(s):  
Quality Of Life ◽  
Dry Eye ◽  
Ocular Surface ◽  
Cross Sectional Study ◽  
Dry Eye Syndrome ◽  
Control Group ◽  
Ocular Surface Disease Index ◽  
Symptom Scale ◽  
Cross Sectional

Purpose To verify the presence of dry eye syndrome (DES) in treated patients with glaucoma and to analyze DES's impact on the patients' quality of life (QOL) versus the control group. Methods In this observational cross-sectional study, 61 patients were enrolled at a clinical practice. Patients were divided into three groups by number of glaucoma drops instilled per day (G1=1 drop/day, G2=2 drops/day, G3=3 drops/day). A control group of 20 subjects was also selected (G0). All subjects were submitted to a complete ocular examination (including tear function and ocular surface status) and completed the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ), Glaucoma Symptom Scale (GSS) questionnaire, and Ocular Surface Disease Index (OSDI). DES was defined as presence of punctate keratitis and decreased break-up time. Statistical analysis was performed applying the Kruskal-Wallis analysis of variance and Mann-Whitney U tests (to compare median values between groups) as well as the χ2 and Fisher test (to verify significant differences). Results A total of 40% of G3 and 39% of G2 patients presented DES versus 11% of G1 and 5% of G0 (p=0.01). QOL was significantly influenced and altered (NEI-VFQ 25 total mean and GSS total mean and symptoms average: p=0.0085, p=0.006, and p=0.03, respectively). OSDI pointed out differences by group: 26% of G2 and 15% of G3 presented moderate OSDI and 15% of G3 and 8.7% of G2 severe OSDI (p>0.05). Conclusions Patients with topically treated glaucoma present DES more often than a similar control group (p=0.01). The presence of DES negatively influences the patient's QOL. The patients with glaucoma's ocular surface status should be evaluated regularly to ensure the timely detection and treatment of pathologic signs on the ocular surface.

scholarly journals Cationic Thiolated Poly(aspartamide) Polymer as a Potential Excipient for Artificial Tear Formulations

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Mária Budai-Szűcs ◽  
Gabriella Horvát ◽  
Barnabás Áron Szilágyi ◽  
Benjámin Gyarmati ◽  
András Szilágyi ◽  
...  
Keyword(s):  
Dry Eye ◽  
Tear Film ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Eye Drops ◽  
Thiol Groups ◽  
Physiological Properties ◽  
Disulphide Bond Formation ◽  
Polymer Bearing

Dry eye disease is a relatively common ocular problem, which causes eye discomfort and visual disorders leading to a decrease in the quality of life. The aim of this study was to find a possible excipient for eye drop formulations, which is able to stabilize the tear film. A cationic thiolated polyaspartamide polymer, poly[(N-mercaptoethylaspartamide)-co-(N-(N′,N′-dimethylaminoethyl)aspartamide)] (ThioPASP-DME), was used as a potential vehicle. Besides satisfying the basic requirements, the chemical structure of ThioPASP-DME is similar to those of ocular mucins as it is a protein-like polymer bearing a considerable number of thiol groups. The solution of the polymer is therefore able to mimic the physiological properties of the mucins and it can interact with the mucus layer via disulphide bond formation. The resultant mucoadhesion provides a prolonged residence time and ensures protective effect for the corneal/conjunctival epithelium. ThioPASP-DME also has an antioxidant effect due to the presence of the thiol groups. The applicability of ThioPASP-DME as a potential excipient in eye drops was determined by means of ocular compatibility tests and through examinations of the interactions with the mucosal surface. The results indicate that ThioPASP-DME can serve as a potential eye drop excipient for the therapy of dry eye disease.

Sign in / Sign up

Export Citation Format

Share Document